HYDERABAD/BENGALURU (Reuters) -Sun Pharmaceutical, India's largest drugmaker by revenue, reported a bigger-than-expected ...

December quarter earnings brought a mixed bag of surprises across sectors. While rural demand revival lifted consumer-driven ...

Sun Pharmaceutical Industries Ltd. closed 13.04% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharma's Q3 earnings may see a slight setback in margins, pressured by increased R&D expenses and a lower contribution from cancer drug Revlimid.

Net Sales at Rs 13,675.46 crore in December 2024 up 10.46% from Rs. 12,380.70 crore in December 2023. Quarterly Net Profit at ...

Results: Sun Pharmaceutical Industries on Friday said its consolidated net profit increased 15 per cent on-year to Rs 2,903 crore in the December quarter, riding on robust sales across geographies.

Shares of Sun Pharmaceutical Industries Ltd. 524715 rallied 3.12% to 1,746.50 Indian rupees Thursday, on what proved to be an all-around grim trading session for the stock market, with the BSE SENSEX ...

Sun Pharma's US formulation sales stood at $474 million during the quarter, which was lower than the expectations of $516 ...

The drug major will appeal against the order. Shares of Sun Pharmaceutical Industries Ltd ended at ₹1,762.90, up by ₹22.95, ...

Our market share gain in India has been driven by industry-leading volume growth," said Dilip Shanghvi, Chairman and MD, Sun Pharma. For the India formulation business, sales increased by 14 per ...

Sun Pharmaceutical Industries has elevated Aalok Shanghvi, son of the drugmaker’s founder promoter Dilip Shanghvi, as the Chief Operating Officer. Aalok (40 years), continues as Whole-time ...

Aalok Shanghvi completed his graduation in Cellular and Molecular Biology from the University of Michigan, US.